Accelerating the manufacturing of HIV Env protein vaccines for early phase clinical evaluation
This commentary discusses the benefits in terms of time savings and reduced costs of goods in using transient electroporation and immuno-affinity purification as an alternative to the traditional manufacturing approaches for the CGMP manufacturing of HIV Envelope protein immunogens for use in invest...
Saved in:
| Main Author: | Michael N. Pensiero |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-08-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-025-01169-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Accelerated cGMP production of near-native HIV-1 Env trimers following electroporation transfection and immunogenicity analysis
by: Shridhar Bale, et al.
Published: (2025-08-01) -
Env-pseudoviruses based on the HIV-1 genetic variant circulating in Siberia
by: N. B. Rudometova, et al.
Published: (2025-07-01) -
«FREE» AND «BOUND» ANTIBODIES AGAINST HIV–1 STRUCTURE PROTEINS AT EARLY STAGE OF THE DISEASE
by: G. A. Rjazanova, et al.
Published: (2014-07-01) -
Increasing early phase clinical trials capacity in India
by: Jerin Jose Cherian, et al.
Published: (2025-07-01) -
Accelerating vaccine development: Plug-and-play platforms for emerging infectious diseases
by: Kairui Yang
Published: (2025-08-01)